The biotech industry hit a speed bump in 2016 after logging accelerating growth for years. US drug approvals fell to just 22 – from 45 in 2015 – a six-year low.
Category: Sirna Therapeutics
Here’s Why Alnylam Pharmaceuticals Plunged 59.8% in 2016
A major clinical setback removed a potential blockbuster drug from Alnylam’s pipeline and led to a collapse in the company’s share price. . Shares of the RNAi-focused biotech utterly collapsed, falling by nearly 60% during the year, according to data from S&P Global Market Intelligence .
Here’s Why Alnylam Pharmaceuticals Plunged 59.8% in 2016
A major clinical setback removed a potential blockbuster drug from Alnylam’s pipeline and led to a collapse in the company’s share price. . Shares of the RNAi-focused biotech utterly collapsed, falling by nearly 60% during the year, according to data from S&P Global Market Intelligence .